FTSV Forty Seven Inc.

94.55
+0.08  (+0%)
Previous Close 94.47
Open 94.3
Price To Book 14.33
Market Cap 4,553,173,532
Shares 48,156,251
Volume 1,766,593
Short Ratio
Av. Daily Volume 1,841,210
Stock charts supplied by TradingView

NewsSee all news

  1. Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

    -- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket

  2. Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

    MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV) and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced today that they have entered into a research collaboration to

  3. Gilead to Acquire Forty Seven for $4.9 Billion

    – Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma – –

  4. Forty Seven to Present at Upcoming Investor Conferences in March

    MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  5. Forty Seven to Present at Upcoming Investor Conferences in February

    MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Registration-enabling trial initiated 1Q 2020 with interim data due 2H 2020.
Magrolimab + rituximab
Diffuse Large B-Cell Lymphoma
Phase 1b data presented at ASCO-GI January 25, 2020. In KRASm patients, there were no responses but 45% had stable disease (SD).
Magrolimab + cetuximab
Colorectal cancer
Phase 1b data at ASCO June 3, 2019 noted 10% ORR.
5F9
Acute myeloid leukemia (AML)
Phase 1b updated data due mid-2020.
Magrolimab + Azacitidine
Acute myeloid leukemia (AML)
Phase 1 trial ongoing.
5F9
Solid tumors
Phase 1b due at ASCO-SITC February 6, 2020 - 0% ORR in 18 ovarian cancer patients.
Magrolimab + Avelumab
Ovarian cancer
Phase 3 trial to be initiated 2Q 2020. Phase 1b updated data due mid-2020.
Magrolimab + Azacitidine
Higher risk-Myelodysplastic Syndrome (MDS)

Latest News

  1. Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

    -- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket

  2. Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

    MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV) and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced today that they have entered into a research collaboration to

  3. Gilead to Acquire Forty Seven for $4.9 Billion

    – Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma – –

  4. Forty Seven to Present at Upcoming Investor Conferences in March

    MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  5. Forty Seven to Present at Upcoming Investor Conferences in February

    MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  6. Forty Seven Announces 2020 Strategic Priorities and Expected Milestones

    -- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b Trial in Higher-Risk

  7. Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares

    MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 5,589,000

  8. Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock

    MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of

  9. Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock

    MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $140,000,000 of

  10. Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors

    DUBLIN, Ireland, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating

  11. Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation

    -- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 ---- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE)

  12. Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

    -- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS ---- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction Chemotherapy ----

  13. Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    -- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 ---- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin

  14. bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (NASDAQ:BLUE) and Forty Seven, Inc. (NASDAQ:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based

  15. Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  16. Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today

  17. Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference

    MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  18. Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  19. Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

    MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced